Alpa Laboratories Ltd Stock Price Today (NSE: ALPA)
Fundamental Score
Alpa Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Alpa Laboratories Ltd share price today is ₹51.75, up +3.07% on NSE/BSE as of 15 April 2026. Alpa Laboratories Ltd (ALPA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹160.35 (Cr). The 52-week high for ALPA share price is ₹120.50 and the 52-week low is ₹46.10. At a P/E ratio of 8.59x, ALPA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.09% and a debt-to-equity ratio of 0.00.
Alpa Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap pharma play with a busted balance sheet and zero margin for error; avoid before it implodes.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): Alpa Laboratories faced scrutiny regarding a significant price movement, prompting the exchange to seek clarification on April 8, 2026. The company's Q3 FY26 results showed a net profit of ₹1.90 Cr, a substantial QoQ increase of 1,627.27% from ₹0.11 Cr in Q2 FY26, but a concerning 78.65% YoY decline. Revenue for Q3 FY26 stood at ₹29.05 Cr, reflecting an 11.09% YoY increase. 🧠 CORE STORY (THE REAL GAME): Alpa Labs is being priced as a deeply troubled micro-cap pharma play attempting a turnaround, but struggling with consistent profitability. The market is hyper-focused on whether they can fix their operational inefficiencies and sustain any profit recovery. 🔥 WHAT IS DRIVING THE STOCK: 1. **Q3 Profit Recovery:** The massive QoQ jump in net profit (1,627.27%) from near zero base, fueled initial positive sentiment. 2. **Revenue Growth:** A modest 11.09% YoY revenue increase in Q3 FY26 suggests some top-line momentum. 3. **Valuation Discount:** P/E of 8.59x vs. industry P/E of 31.77x might attract value hunters. ⚖️ BULL vs BEAR: Bull: Deep value play. Q3 profit recovery is real, not a fluke. Operational improvements and cost-cutting drive margin expansion. Low valuation provides a margin of safety. Bear: Q3 YoY profit decline of 78.65% highlights deeper issues. Inconsistent profitability and reliance on non-operating income raise sustainability questions. Micro-cap equals high liquidity risk. 💣 WHAT MARKET IS PRICING: The market is pricing in a high probability of failure. Any sign of sustained profitability and margin improvement will trigger a rally. Failure to do so will lead to new lows. 🎯 BOTTOM LINE: Alpa Labs is a micro-cap gamble on a turnaround story with a high chance of implosion. Liquidity is a major concern. Avoid.
- Q3 FY26 profit recovery is likely unsustainable
- YoY profit decline of 78.65% signals deeper problems
- Micro-cap liquidity risk is too high
- Sustained margin expansion
- Significant order wins
- Successful debt restructuring
- Micro-cap with limited liquidity
- Inconsistent profitability and reliance on non-operating income
- Resignation of Company Secretary/Compliance Officer
FII down 0.01% — not a good sign.
Indian pharma exports are growing, but Alpa Labs isn't benefiting.
Poor. ₹15.17 Cr FCF over 5 years is weak.
Next 3-6 months will determine if Alpa Labs can turn things around, but the odds are stacked against them. Expect continued volatility and potential downside.
Primary Thesis Risk
Inability to improve operational efficiency and manage costs will lead to insolvency.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Alpa Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Alpa Laboratories Share Price: A Conservative Value Investor's Perspective
Within the pharmaceutical sector, a crucial differentiator lies in the ability to navigate complex regulatory landscapes and maintain robust research & development pipelines. Successful navigation translates directly into consistent revenue streams. This analysis examines the "Alpa Laboratories share price" from the perspective of a conservative value investor prioritizing capital safety and long-term sustainability. At a current price of ₹71.5, and a PE ratio of 8.59, Alpa Laboratories presents an interesting proposition, particularly when considering the broader industry valuations.
One of the key metrics I assess is Return on Capital Employed (ROCE). Alpa Laboratories boasts a ROCE of 15.79%. This indicates the company's efficiency in generating profits from its invested capital. A consistently high ROCE, like the one exhibited by Alpa Laboratories, can contribute to building an economic moat, making it harder for competitors to erode profitability. It suggests a degree of pricing power and operational efficiency that should continue to be monitored closely.
Compared to its peers, Alpa Laboratories' valuation demands deeper scrutiny. While
Mankind Pharma Ltd may trade at a premium due to perceived superior management quality, brand recognition, and a higher growth trajectory, the lower PE of Alpa Laboratories might present an opportunity if future growth is unlocked. However, a lower PE can also reflect market concerns about future growth prospects or perceived risks. The key here is to understand why the market is applying a lower multiple to Alpa Laboratories compared to its peers, potentially due to differing investor perceptions on management ability.This analysis forms part of a comprehensive, 80-parameter fundamental audit personally verified by Sweta Mishra, focusing on aspects like financial health, operational efficiency, and corporate governance. The objective is to assess the inherent value of Alpa Laboratories Ltd. It's crucial to remember this is an observational analysis based on publicly available data and is not intended as investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Alpa Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ALPA across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (15.79%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 8.59 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (49.23% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (49.23% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (121.32x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (57.29%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-98.57%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 0.35%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Alpa Laboratories Ltd Financial Statements
Comprehensive financial data for Alpa Laboratories Ltd including income statement, balance sheet and cash flow
About ALPA (Alpa Laboratories Ltd)
Alpa Laboratories Ltd is a dynamic pharmaceutical company rooted in Indore, India, dedicated to the development, manufacturing, and distribution of a diverse range of pharmaceutica...l products. With a history stretching back to its incorporation, the company has steadily cultivated a reputation for quality and reliability within the Indian pharmaceutical landscape. Alpa Laboratories focuses on providing accessible and effective medications, aiming to cater to a broad spectrum of healthcare needs across various therapeutic areas. Their commitment to rigorous quality control and adherence to industry best practices ensures that their products meet the highest standards of safety and efficacy, solidifying their position as a trusted provider in the market. The company's enduring presence speaks to its commitment to innovation and service within the ever-evolving healthcare sector. Alpa Laboratories is characterized by its dedication to producing formulations that cover a wide range of therapeutic segments. This encompasses areas such as pain management, cardiovascular health, and anti-infectives, showcasing the company's breadth and ability to address numerous prevalent health concerns. The company demonstrates an understanding of the healthcare challenges facing India and strives to provide solutions through its comprehensive product portfolio. This diverse offering allows Alpa Laboratories to serve a broad patient base and contribute meaningfully to improved healthcare outcomes across the country. The firm's commitment to expanding its therapeutic reach underscores its ambition to be a significant contributor to the health and well-being of the Indian population. At its core, Alpa Laboratories operates with a vision of enhancing patient lives through access to quality pharmaceuticals. While firmly established in Indore, the company's influence extends across India, reaching patients and healthcare providers alike. Their established infrastructure and distribution network enable them to effectively deliver their products to various markets, ensuring accessibility and timely availability. Alpa Laboratories' steady growth trajectory reflects its focus on sustainable practices, continuous improvement, and a dedication to meeting the evolving needs of the healthcare industry. This unwavering commitment to excellence positions Alpa Laboratories for continued success and growth in the years to come.
Company Details
Key Leadership
ALPA Share Price: Frequently Asked Questions
What is the current share price of Alpa Laboratories Ltd (ALPA)?
As of 15 Apr 2026, 11:00 am IST, Alpa Laboratories Ltd share price is ₹51.75. The ALPA stock has a market capitalisation of ₹160.35 (Cr) on NSE/BSE.
Is ALPA share price Overvalued or Undervalued?
ALPA share price is currently trading at a P/E ratio of 8.59x, compared to the industry average of 31.77x. Based on this relative valuation, the Alpa Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ALPA share price?
The 52-week high of ALPA share price is ₹120.50 and the 52-week low is ₹46.10. These values are updated daily from NSE/BSE price data.
What factors affect the Alpa Laboratories Ltd share price?
Key factors influencing ALPA share price include quarterly earnings growth (Sales Growth: 5.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Alpa Laboratories Ltd a good stock for long-term investment?
Alpa Laboratories Ltd shows a 5-year Profit Growth of 49.23% and an ROE of 12.09%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in ALPA shares.
How does Alpa Laboratories Ltd compare with its industry peers?
Alpa Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare ALPA share price P/E of 8.59x and ROE of 12.09% against the industry averages to determine competitive standing.
What is the P/E ratio of ALPA and what does it mean?
ALPA share price has a P/E ratio of 8.59x compared to the industry average of 31.77x. Investors pay ₹9 for every ₹1 of annual earnings.
How is ALPA performing according to Bull Run's analysis?
ALPA has a Bull Run fundamental score of 55.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ALPA belong to?
ALPA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alpa Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for ALPA?
ALPA has an ROE of 12.09%, which shows decent profitability but room for improvement. ROE measures how efficiently Alpa Laboratories Ltd generates profits from shareholders capital.
How is ALPA debt-to-equity ratio and what does it indicate?
ALPA has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is ALPA dividend yield and is it a good dividend stock?
ALPA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Alpa Laboratories Ltd shares.
How has ALPA share price grown over the past 5 years?
ALPA has achieved 5-year growth rates of: Sales Growth 5.24%, Profit Growth 49.23%, and EPS Growth 49.23%.
What is the promoter holding in ALPA and why does it matter?
Promoters hold 57.29% of ALPA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Alpa Laboratories Ltd.
What is ALPA market capitalisation category?
ALPA has a market capitalisation of ₹160 crores, placing it in the Small-cap category.
How volatile is ALPA stock?
ALPA has a beta of N/A. A beta > 1 suggests the Alpa Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ALPA operating profit margin trend?
ALPA has a 5-year average Operating Profit Margin (OPM) of 7.66%, indicating the company's operational efficiency.
How is ALPA quarterly performance?
Recent quarterly performance shows Alpa Laboratories Ltd YoY Sales Growth of 5.29% and YoY Profit Growth of -98.57%.
What is the institutional holding pattern in ALPA?
ALPA has FII holding of 0.35% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Alpa Laboratories Ltd stock.